Opal Wealth Advisors LLC Sells 53 Shares of Eli Lilly and Company (NYSE:LLY)

Opal Wealth Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 1st quarter, HoldingsChannel.com reports. The fund owned 963 shares of the company’s stock after selling 53 shares during the period. Opal Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $795,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. FPC Investment Advisory Inc. raised its position in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $43,000. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the 4th quarter worth about $48,000. Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $63,000. Finally, Bellwether Advisors LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $66,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $818.56 on Friday. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock’s 50 day moving average price is $775.43 and its 200-day moving average price is $801.50. The company has a market capitalization of $775.78 billion, a PE ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the previous year, the firm earned $2.58 EPS. Eli Lilly and Company’s quarterly revenue was up 45.2% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a $1.50 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. Eli Lilly and Company’s payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.